Eloxx Pharmaceuticals Inc

-0.01 (-2.94%)
Earnings Announcements

Eloxx Pharmaceuticals Reports Q1 Loss Per Share Of $0.13

Published: 05/10/2022 12:21 GMT
Eloxx Pharmaceuticals Inc (ELOX) - Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update.
Qtrly Loss per Share $0.13.
On Track to Start Human Phase 1 Study in 2022 With Zkn-013 for Treatment of Recessive Dystrophic Epidermolysis Bullosa.
Cash and Equivalents Expected to Be Sufficient to Fund Operations Into the Second Quarter of 2023.
Q2 Earnings per Share View $-0.12 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $2.33 Million
Adjusted EPS is expected to be -$0.12

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.12

More details on our Analysts Page.